Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ADH5 | P11766 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 2/20 | 0.44 |
| ▸ | F9 | P00740 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | CD38 | P28907 | 5/20 | 0.40 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7082587 | 0.99 | CYP1A2 (0.46) | CYP1A2ALDH1A1CYP2C19LMNAMEN1 | |
| SCHEMBL3972148 | 0.91 | CYP1A2 (0.49) | CYP1A2ALDH1A1CYP2C19LMNAMEN1 | |
| SCHEMBL3974651 | 0.86 | ALDH1A1 (0.44) | CYP1A2ALDH1A1CYP2C19LMNAMEN1 | |
| Hydrochloric Acid SCHEMBL3971651 | 0.85 | ALDH1A1 (0.43) | CYP1A2ALDH1A1CYP2C19LMNAMEN1 | |
| SCHEMBL3972141 | 0.82 | CYP3A4 (0.47) | CYP1A2ALDH1A1CYP2C19LMNAMEN1 | |
| SCHEMBL3974655 | 0.81 | SLC9A1 (0.44) | CYP1A2ALDH1A1CYP2C19LMNAMEN1 | |
| SCHEMBL3531980 | 0.80 | ADH5 (0.66) | CYP1A2ALDH1A1CYP2C19LMNAMEN1 | |
| Hydrochloric Acid SCHEMBL6837522 | 0.80 | SLC9A1 (0.44) | CYP1A2ALDH1A1CYP2C19LMNAMEN1 | |
| SCHEMBL1764050 | 0.76 | SLC9A1 (0.73) | CYP2C19CYP3A4CYP2D6CYP2C9SLC9A1 | |
| SCHEMBL1763741 | 0.74 | SLC9A1 (0.49) | CYP2C19CYP2D6MAPTCYP2C9ADH5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6617344-B2 | Suitable as antiarrhythmic pharmaceuticals having a cardioprotective component for infarct prophylaxis and infarct treatment, and also for the treatment of angina pectoris. | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-09-09 | — | — | US | disclosed |
| US-20030139607-A1 | HETEROCYCLICALLY SUBSTITUTED BENZOYLGUANIDINES, PROCESS FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS OR DIAGNOSTICS, AND MEDICAMENTS COMPRISING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-07-24 | — | — | US | disclosed |
| EP-1226124-A1 | HETEROCYCLICALLY SUBSTITUTED BENZOYLGUANIDINE, METHOD FOR THE PRODUCTION THEREOF, THE USE THEREOF AS A MEDICAMENT OR MEANS OF DIAGNOSIS AND A MEDICAMENT CONTAINING THE SAME | Aventis Pharma Deutschland GmbH (DE) | 2002-07-31 | — | — | EP | disclosed |
| US-20020099222-A1 | Heterocyclically substituted benzoylguanidines, process for their preparation, their use as medicaments or diagnostics, and medicaments comprising them | WEICHERT ANDREAS (DE) | 2002-07-25 | — | — | US | disclosed |
| US-20010049446-A1 | Heterocyclically substituted benzoylguanidines, process for their preparation, their use as medicaments or diagnostics, and medicaments comprising them | WEICHERT ANDREAS (DE) | 2001-12-06 | — | — | US | disclosed |
| WO-2001030761-A1 | HETEROCYCLICALLY SUBSTITUTED BENZOYLGUANIDINE, METHOD FOR THE PRODUCTION THEREOF, THE USE THEREOF AS A MEDICAMENT OR MEANS OF DIAGNOSIS AND A MEDICAMENT CONTAINING THE SAME | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099222-A1 | Heterocyclically substituted benzoylguanidines, process for their preparation, their use as medicaments or diagnostics, and medicaments comprising them | TNNI3, HBG1, TNNT2 | CYP1A2 286/4885ALDH1A1 66/4885CYP2C19 181/4885 |
| US-20010049446-A1 | Heterocyclically substituted benzoylguanidines, process for their preparation, their use as medicaments or diagnostics, and medicaments comprising them | TNNI3, HBG1, TNNT2 | CYP1A2 286/4885ALDH1A1 66/4885CYP2C19 181/4885 |
| US-20030139607-A1 | HETEROCYCLICALLY SUBSTITUTED BENZOYLGUANIDINES, PROCESS FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS OR DIAGNOSTICS, AND MEDICAMENTS COMPRISING THEM | TNNI3, HBG1, TNNT2 | CYP1A2 286/4885ALDH1A1 66/4885CYP2C19 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.